全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

高血压合并颈动脉粥样硬化的中西医治疗进展
Chinese and Western Medicine Treatment Progression between Hypertension and Carotid Atherosclerosis

DOI: 10.12677/ACM.2023.1361273, PP. 9091-9097

Keywords: 高血压,颈动脉粥样硬化,中西医治疗
Hypertension
, Carotid Artery Atherosclerosis, Chinese and Western Medicine Treatment

Full-Text   Cite this paper   Add to My Lib

Abstract:

高血压病作为一种发作较为普遍的心血管疾病,同时也是动脉硬化产生与进展的主要危险来源。颈动脉粥样硬化作为众多心血管疾病的病理基础,伴随着血压水平的升高与动脉硬化水平的加剧,患者发生心肌梗死、脑卒中等心血管不良事件的死亡风险也随之增高,但是早期又以其症状隐匿而不易被发现,从而不能对病情有精准的把握。目前对于该病的治疗,西医方面治疗方案较为繁杂,但仍然主要以药物对症治疗为主,近年来大量临床实验结果显示,在控制血压积极治疗原发病的同时,抗血小板凝集、对血脂进行有效调节均能提高临床疗效。中医的整体观念、辨证论治思想为该疾病的诊断与治疗提供很多新思路。
Hypertension, as a common cardiovascular disease with frequent outbreaks, is also the main risk factor for the development and progression of arteriosclerosis. Carotid atherosclerosis, as the pathological basis of many cardiovascular diseases, is accompanied by an increase in blood pressure and arterial atherosclerosis. The risk of death from cardiovascular events such as myocardial in-farction and stroke also increases. However, in the early stage, it is characterized by hidden symp-toms and is not easily detected, so it cannot be accurately grasped. Currently, the Western medicine treatment plan for this disease is relatively complicated, but it is still mainly based on symptomatic treatment with drugs. In recent years, a large number of clinical trial results have shown that con-trolling blood pressure while actively treating the primary disease, anti-platelet aggregation, and effective regulation of blood lipid levels can improve clinical efficacy. The overall concept and the treatment of syndrome differentiation in traditional Chinese medicine provide many new ideas for the diagnosis and treatment of this disease.

References

[1]  Ko?akowska, U., Kuroczycka-Saniutycz, E., Olański, W. and Wasilewska, A. (2018) Correlation of Salusin Beta with hs-CRP and ADMA in Hypertensive Children and Adolescents. Current Pharmaceutical Design, 24, 3551-3557.
https://doi.org/10.2174/1381612824666180607124531
[2]  付丽娟, 黄玮, 吴侠, 陈磊. 颈动脉彩色多普勒超声检测老年患者颈动脉病变及与高血压的相关性研究[J]. 影像科学与光化学, 2021, 39(3): 446-449.
[3]  Chi, X., Li, M., Zhan, X., et al. (2018) Relationship between Carotid Artery Sclerosis and Blood Pressure Variability in Essential Hypertension Patients. Computers in Biology and Medicine, 92, 73-77.
https://doi.org/10.1016/j.compbiomed.2017.03.012
[4]  梁营营, 张娟, 秦瑞丹. 原发性高血压患者血压变异性及Lp-PLA2、sdLDL-C与颈动脉硬化程度的相关性[J]. 中国医学创新, 2022, 19(31): 10-16.
[5]  Hisamatsu, T., Miura, K., Ohkubo, T., et al. (2018) Home Blood Pressure Variability and Subclinical Atherosclerosis in Multiple Vas-cular Beds: A Population-Based Study. Journal of Hypertension, 36, 2193-2203.
https://doi.org/10.1097/HJH.0000000000001810
[6]  Li, C.L., Liu, R., Wang, J.R. and Yang, J. (2017) Relation-ship between Blood Pressure Variability and Target Organ Damage in Elderly Patients. European Review for Medical and Pharmacological Sciences, 21, 5451-5455.
[7]  王飞, 鲍婷婷, 龚梅, 等. 高血压患者清晨高血压与颈动脉内中膜厚度增加及斑块形成的关系[J]. 泰州职业技术学院学报, 2022, 22(6): 84-86+93.
[8]  杨智琳, 王立平, 黄菊, 等. 血管生成素样蛋白8介导高血压促进动脉粥样硬化形成机制[J]. 国际心血管病杂志, 2022, 49(6): 341-343.
[9]  Abu-Farha, M., Cherian, P., Qaddoumi, M.G., et al. (2018) Increased Plasma and Adipose Tissue Levels of ANGPTL8/Betatrophin and ANGPTL4 in People with Hypertension. Lipids in Health and Disease, 17, Article No. 35.
https://doi.org/10.1186/s12944-018-0681-0
[10]  沈冬英. 彩色多普勒超声检查分析原发性高血压与颈动脉粥样硬化的相关性[J]. 影像技术, 2022, 34(6): 15-20.
[11]  Fadaei, R., Shateri, H., DiStefano, J.K., et al. (2020) Higher Circulating Levels of ANGPTL8 Are Associated with Body Mass Index, Triglycerides, and Endothelial Dysfunction in Patients with Coronary Artery Disease. Molecular and Cellular Biochemistry, 469, 29-39.
https://doi.org/10.1007/s11010-020-03725-7
[12]  孙喜文. 高血压合并动脉粥样硬化患者血清CysC、Hcy的表达及临床意义[J]. 中国实用医药, 2022, 17(23): 33-36.
[13]  王爱亮, 夏卫明, 蔡群, 高想. 高血压病患者颈动脉粥样硬化程度与血清同型半胱氨酸水平的相关性分析[J]. 心脑血管病防治, 2021, 21(3): 291-292.
[14]  司大妞. 原发性高血压患者血清甲壳质酶蛋白40、生长分化因子15水平与颈动脉粥样硬化的关系[J]. 中国医学工程, 2021, 29(9): 40-43.
https://doi.org/10.19338/j.issn.1672-2019.2021.09.010
[15]  齐婧, 王永刚, 郑刚. 颈动脉粥样硬化性狭窄中医证候调查分析[J]. 陕西中医学院学报, 2011, 34(6): 6-8.
https://doi.org/10.13424/j.cnki.jsctcm.2011.06.007
[16]  王蕾, 尚倩倩, 钱鹏, 郭睿, 王忆勤, 燕海霞. 高血压病患者动态动脉硬化指数的研究现状及对中医脉诊研究的启示[J]. 中华中医药杂志, 2017, 32(11): 4793-4797.
[17]  李秀华. 复方三七护脉汤治疗高血压病伴动脉粥样硬化临床观察[J]. 中国中医药现代远程教育, 2022(22): 83-86.
[18]  谢盈彧, 张军平, 仲爱芹, 王爱迪, 田立俊. 从痰瘀立论探讨分期治疗颈动脉粥样硬化[J]. 中华中医药杂志, 2017, 32(1): 101-104.
[19]  刘金, 姚淮芳, 张叶祥, 张松. 姚淮芳教授补肾活血法治疗动脉粥样硬化经验[J]. 中西医结合心脑血管病杂志, 2018, 16(18): 2751-2752.
[20]  吴以岭, 贾振华, 常丽萍, 魏聪. 脉络学说营卫理论指导血管病变防治研究[J]. 中国实验方剂学杂志, 2019, 25(1): 1-10.
https://doi.org/10.13422/j.cnki.syfjx.20190199
[21]  李雅文, 常丽萍, 秘红英, 王康, 尹玉洁, 贾振华. 基于脉络学说探析慢性冠脉综合征的病机及治疗[J]. 中国实验方剂学杂志, 2021, 27(1): 196-202.
https://doi.org/10.13422/j.cnki.syfjx.20202451
[22]  Bartlett, L.E., Pratt, N. and Roughead, E.E. (2018) Does a Fixed-Dose Combination of Amlodipine and Atorvastatin Improve Persistence with Therapy in the Australian Population? Current Medical Research and Opinion, 34, 305-311.
https://doi.org/10.1080/03007995.2017.1384375
[23]  周海民. 探究氯吡格雷联合阿托伐他汀钙治疗高血压合并颈动脉粥样硬化的疗效观察[J]. 临床医药文献电子杂志, 2020, 7(23): 150.
https://doi.org/10.16281/j.cnki.jocml.2020.23.145
[24]  赵素贞, 谢桥涛. 阿托伐他汀联合依那普利叶酸对高血压伴颈动脉粥样硬化老年患者血清学指标及颈动脉狭窄程度的影响[J]. 医学理论与实践, 2021, 34(19): 3361-3363.
https://doi.org/10.19381/j.issn.1001-7585.2021.19.021
[25]  黄剑锋, 肖善花, 李悦, 等. 马来酸依那普利叶酸片联合阿托伐他汀干预H型高血压合并颈动脉粥样硬化高危病人脑卒中发作的临床研究[J]. 中西医结合心脑血管病杂志, 2022, 20(23): 4351-4354.
[26]  莫秀丽. 拉西地平与替米沙坦治疗高血压患者颈动脉粥样硬化的临床研究[J]. 黑龙江医药, 2020, 33(1): 42-44.
https://doi.org/10.14035/j.cnki.hljyy.2020.01.018
[27]  杨冬梅, 张璐, 张念彩. 西拉普利联合拉西地平对高血压患者血管活性物质和颈动脉粥样硬化的影响[J]. 中国循证心血管医学杂志, 2020, 12(2): 214-216+220.
[28]  张万强, 刘冰. 氨氯地平阿托伐他汀钙片治疗高血压、冠心病合并颈动脉粥样硬化的临床效果观察[J]. 中国实用医药, 2022, 17(25): 125-127.
https://doi.org/10.14163/j.cnki.11-5547/r.2022.25.035
[29]  陈健, 王旺, 刘智洋. 苯磺酸氨氯地平联合他汀类药物治疗高血压伴颈动脉粥样硬化的效果[J]. 中国临床医生杂志, 2021, 49(12): 1422-1424.
[30]  常先松, 肖文金. 祛瘀化痰通脉方治疗高血压合并颈动脉粥样硬化的疗效及对血脂水平的影响[J]. 中药材, 2023(2): 499-502.
https://doi.org/10.13863/j.issn1001-4454.2023.02.040
[31]  桂明泰, 曹慧, 钱佳, 等. 加味越鞠丸对高血压患者颈动脉粥样硬化、血脂及炎性因子的影响[J]. 陕西中医, 2022, 43(2): 181-184.
[32]  任耀龙, 杨磊, 赵明君, 等. 丹黄通脉胶囊稳定原发性高血压患者颈动脉易损斑块的临床效果[J]. 中医药导报, 2022, 28(12): 105-109.
https://doi.org/10.13862/j.cn43-1446/r.2022.12.020
[33]  占文明, 闫旭. 银杏叶胶囊联合奥拉西坦治疗H型高血压合并颈动脉粥样硬化的临床分析[J]. 山西医药杂志, 2021, 50(15): 2310-2314.
[34]  孙鲲, 宋文超, 周文恒. 益气活血通脉法联合阿托伐他汀对高血压病颈动脉粥样硬化患者血清脂蛋白相关磷脂酶A2、趋化因子配体与氧化应激指标影响[J]. 辽宁中医药大学学报, 2020, 22(4): 166-169.
https://doi.org/10.13194/j.issn.1673-842x.2020.04.041
[35]  廖锐, 倪卫, 林德智. 银杏酮酯滴丸联合阿托伐他汀对高血压伴颈动脉硬化患者血管内皮功能、血清网膜素-1和Hcy的影响[J]. 心血管康复医学杂志, 2019, 28(3): 364-368.
[36]  杨尚磊, 黄丽娟. 氨氯地平阿托伐他汀钙片联合血府逐瘀软胶囊治疗原发性高血压合并颈动脉粥样硬化患者的疗效观察[J]. 世界中西医结合杂志, 2021, 16(1): 108-112+118.
https://doi.org/10.13935/j.cnki.sjzx.210124
[37]  叶萍, 胡华青, 侯勇, 等. 血府逐瘀软胶囊联合常规治疗对高血压伴颈动脉粥样硬化患者的临床疗效[J]. 中成药, 2019, 41(12): 2898-2901.
[38]  胡宗仁, 谢常林, 卢健胜. 滋阴潜阳辩证治疗顽固性高血压病合并颈动脉粥样硬化患者的效果及其对NO、CGRP及中医证候评分的影响[J]. 海峡药学, 2019, 31(11): 121-122.
[39]  覃晓红. 潜阳育阴颗粒对阴虚阳亢型高血压病患者颈动脉血管弹性功能的临床疗效观察[D]: [硕士学位论文]. 南京: 南京中医药大学, 2020.
https://doi.org/10.27253/d.cnki.gnjzu.2020.000345
[40]  尚德师, 郭强. 平肝化浊浴足方干预高血压病人血浆致动脉硬化指数及颈动脉内膜-中层厚度的临床研究[J]. 中西医结合心脑血管病杂志, 2020, 18(3): 494-496.
[41]  徐盛颖, 王道成, 王国平, 等. 复方三七通脉方治疗高血压早期肾损害伴颈动脉粥样硬化的临床研究[J]. 中医药导报, 2021, 27(5): 73-77.
https://doi.org/10.13862/j.cnki.cn43-1446/r.2021.05.014

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133